Redefining Musculoskeletal Pain Management through Targeted, Non-Opioid Biologics
Our platform delivers biologics precisely to the site of injury, designed to modulate acute pain mediators at the tissue level where it starts.
A True Non-Opioid Alternative
Designed to reduce opioid reliance through targeted, biologic intervention that supports safer, faster relief.
Clinical Trials Launching 2026
ARCK will initiate multi-site US phase III clinical trials to evaluate safety, efficacy, and biologic impact in multiple indications of acute musculoskeletal pain.
Our Story
ARCK Biologics was founded to confront the opioid crisis directly by advancing a targeted biologic alternative designed for acute musculoskeletal injury care. Drawing on decades of experience in orthopedics, regenerative medicine, and biologic engineering, ARCK’s leadership team is leveraging FDA-approved biologic science and indication-specific intellectual property to meet real-world clinical needs.
Our Mission
Transforming Acute Pain Care
Redefine acute musculoskeletal pain management through targeted, non-opioid biologic solutions delivering lasting relief and faster recovery without systemic exposure or dependency risk.
Our Science
This biologic therapy harnesses signaling to engage damaged tissues, modulate pain pathways, and support recovery—all without relying on systemic analgesics.
Precision
Non-Opioid
Biologic Therapy
Targeted one and done treatment resulting in no clinical systemic effects, no organ failure or bleeding, no addiction, and no cognitive impairment.
For Investors
ARCK Biologics is positioned to lead a rapidly expanding market in non-opioid MSK pain management. Our proprietary IP, utilization strategy, proven leadership team, and distinguished advisory boards create a compelling investment opportunity.
•Scalable Adoption
• Defensible Science
• Experienced Surgeons
Building the Next Generation of Acute Pain Care
Advancing a targeted, non-opioid biologic platform designed to redefine how acute musculoskeletal pain is treated—safely, precisely, and at scale.
- Targeted – Inject and done
- No patient action required
- No clinical systemic effects
- Non-addictive
- No tolerance development
- No cognitive impairment
Multiple Orthopaedic Indications
Across acute injury, post-operative care, sports medicine, and trauma-related musculoskeletal pain.
Pipeline Expansion
Platform strategy designed to extend beyond acute pain into surgical, chronic, and vascular applications.
2026
Planned clinical milestone year as the program advances toward late-stage evaluation.
Indications
Targeted development across high-impact musculoskeletal and procedural pain settings.
Acute Musculoskeletal Injury
Covers common soft-tissue and joint injuries where localized pain and inflammation drive acute functional limitation. Designed for rapid, tissue-specific pain modulation without systemic exposure.
Example conditions
-
Sprains and strains
-
Ligament and tendon injuries
-
Acute joint trauma
Post-Operative Pain
Addresses acute pain following orthopaedic procedures where early mobilization and opioid-sparing strategies are critical to recovery.
Example procedures
-
Arthroscopy
-
Joint repair and reconstruction
-
Soft-tissue surgical interventions
Sports Medicine & Soft-Tissue Injury
Targets high-demand patients requiring fast recovery and durable pain relief with minimal side-effect risk.
Use cases
-
Athletic injuries
-
Overuse injuries
-
Training-related musculoskeletal stress
Scientific, Clinical, and Corporate Updates
